MCID: KLB004
MIFTS: 31

Klebsiella Infection

Categories: Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Klebsiella Infection

MalaCards integrated aliases for Klebsiella Infection:

Name: Klebsiella Infection 19
Klebsiella 19 75
Klebsiella Infections 71

Classifications:



External Ids:

UMLS 71 C0022729

Summaries for Klebsiella Infection

GARD: 19 Klebsiella is a type of bacteria commonly found in nature. In humans, the bacteria are often present in parts of the digestive tract where they do not generally cause problems. In the United States, Klebsiella pneumoniae and Klebsiella oxytoca are the two strains responsible for most human illnesses. Many Klebsiella infections are acquired in the hospital setting or in long-term care facilities. In fact, Klebsiellae account for up to 8% of all hospital-acquired infections. People with a compromised immune system and/or people who have an implanted medical device (such as a urinary catheter or airway tube) are more at risk for Klebsiella infections. Extensive use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella.

MalaCards based summary: Klebsiella Infection, also known as klebsiella, is related to granuloma inguinale and rhinoscleroma. The drugs Polymyxin B and Ertapenem have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and kidney.

Wikipedia: 75 Klebsiella is a genus of Gram-negative, oxidase-negative, rod-shaped bacteria with a prominent... more...

Related Diseases for Klebsiella Infection

Diseases related to Klebsiella Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 695)
# Related Disease Score Top Affiliating Genes
1 granuloma inguinale 11.2
2 rhinoscleroma 11.0
3 48,xyyy 10.9
4 pneumonia 10.9
5 endophthalmitis 10.8
6 toxic shock syndrome 10.7
7 meningitis 10.7
8 ceroid lipofuscinosis, neuronal, 1 10.6
9 neuronal ceroid-lipofuscinoses 10.6
10 mastitis 10.6
11 osteomyelitis 10.5
12 endocarditis 10.5
13 fasciitis 10.4
14 necrotizing fasciitis 10.4
15 47 xxx syndrome 10.4
16 ataxia with vitamin e deficiency 10.4
17 iron metabolism disease 10.4
18 septic arthritis 10.4
19 lung abscess 10.4
20 respiratory failure 10.4
21 neutropenia 10.4
22 bacteriuria 10.4
23 gastric antral vascular ectasia 10.4
24 bacterial meningitis 10.4
25 infective endocarditis 10.3
26 anterior uveitis 10.3
27 atrophic rhinitis 10.3
28 colitis 10.3
29 uveitis 10.3
30 liver cirrhosis 10.3
31 disseminated intravascular coagulation 10.3
32 enterocolitis 10.3
33 cystitis 10.3
34 adult respiratory distress syndrome 10.3
35 alcohol use disorder 10.3
36 cellulitis 10.3
37 rhinitis 10.3
38 chronic rhinitis 10.3
39 49, xxxxy syndrome 10.3
40 alcohol dependence 10.3
41 bronchopneumonia 10.3
42 hypopyon 10.3
43 pulmonary embolism 10.2
44 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
45 helix syndrome 10.2
46 pleural empyema 10.2
47 permanent neonatal diabetes mellitus 10.2
48 thrombophlebitis 10.2
49 haemophilus influenzae 10.2
50 overgrowth syndrome 10.2

Graphical network of the top 20 diseases related to Klebsiella Infection:



Diseases related to Klebsiella Infection

Symptoms & Phenotypes for Klebsiella Infection

Drugs & Therapeutics for Klebsiella Infection

Drugs for Klebsiella Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polymyxin B Approved, Vet_approved Phase 4 1405-20-5, 1404-26-8 4868
2
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
3
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
4
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
5
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
6
Sulfamethoxazole Approved Phase 4 723-46-6 5329
7
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
8
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
9
Relebactam Approved, Investigational Phase 4 1174018-99-5
10
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415
11
Avibactam Approved Phase 4 1192500-31-4
12
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
13
Tazobactam Approved Phase 4 89786-04-9 123630
14
Piperacillin Approved Phase 4 66258-76-2 43672
15
Ceftriaxone Approved Phase 4 73384-59-5 5479530
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17 Folic Acid Antagonists Phase 4
18 Folate Phase 4
19 Liver Extracts Phase 4
20 Vitamin B9 Phase 4
21 Antiprotozoal Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Vitamin B Complex Phase 4
24 Antimalarials Phase 4
25 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Antibiotics, Antitubercular Phase 4
28 Anti-Bacterial Agents Phase 4
29 beta-Lactamase Inhibitors Phase 4
30 Anti-Infective Agents Phase 4
31 Piperacillin, Tazobactam Drug Combination Phase 4
32
Colistin Approved Phase 3 1264-72-8, 1066-17-7 5311054
33
Tigecycline Approved Phase 3 220620-09-7 5282044
34
Sitafloxacin Experimental, Investigational Phase 2, Phase 3 163253-35-8
35
Lactitol Approved, Investigational Phase 2 585-86-4 157355
36 Cathartics Phase 2
37 Acidophilus Phase 2
38 Laxatives Phase 2
39 Gastrointestinal Agents Phase 2
40 Vaccines Phase 1, Phase 2
41
Fosfomycin Approved Early Phase 1 23155-02-4 446987
42
Framycetin Approved, Experimental, Vet_approved 1404-04-2, 119-04-0, 3947-65-7 413349 8378
43
Streptomycin Approved, Vet_approved 57-92-1 19649
44
Vancomycin Approved 1404-90-6 14969
45
Mineral oil Approved, Vet_approved 8042-47-5
46
Ethanol Approved 64-17-5 702
47 Pharmaceutical Solutions
48 Polymyxins
49 Gentamicins
50 Carboxymethylcellulose Sodium

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study) Unknown status NCT03891433 Phase 4 Meropenem;Ertapenem 1000 MG;Piperacillin, Tazobactam 4-0.5G Solution for Injection
2 Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae Unknown status NCT04489459 Phase 4 Colistin;Meropenem;Tigecycline
3 SELECTIVE DIGESTIVE DECONTAMINATION USING ORAL GENTAMICIN AND ORAL POLYMYXIN E FOR ERADICATION OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE CARRIAGE IN HOSPITALIZED PATIENTS Unknown status NCT01761487 Phase 4
4 A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess Completed NCT01723150 Phase 4 Ciprofloxacin;Ceftriaxone;Trimethoprim/sulfamethoxazole;Ertapenem
5 A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections Recruiting NCT04785924 Phase 4 Imipenem+Relebactam
6 Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species. Terminated NCT02176122 Phase 4 Meropenem;Piperacillin-tazobactam combination product
7 Efficacy and Safety of Colistin for Therapy of Infections Caused by Extended Spectrum Beta-Lactamase(ESBL) Producing Klebsiella Pneumoniae or Escherichia Coli Unknown status NCT00300560 Phase 3 Colistin
8 A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae Completed NCT00079989 Phase 3 tigecycline
9 Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients Recruiting NCT02729116 Phase 2, Phase 3 Sitafloxacin;Ertapenem
10 Safety and Efficacy Study of Eradication of Carbapenem Resistant Klebsiella Pneumonia From the Gastrointestinal Tract by Probiotics. Unknown status NCT00722410 Phase 1, Phase 2 Polyethylene glycol
11 Pilot Study of the Effectiveness of Probiotics and Lactitol for the Intestinal Decolonization of People Carriers of Klebsiella Pneumoniae Producers of Carbapenemase OXA-48-type: DesProbiOXA Study Unknown status NCT02307383 Phase 2 Lactitol;Lactobacillus
12 Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A FTIH Phase I/II Randomized and Controlled Study Completed NCT04959344 Phase 1, Phase 2
13 Randomized, Superiority, Double Blind Controlled With Placebo, Clinical Trial, to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Recruiting NCT04760665 Phase 2
14 A Placebo-Controlled, Blinded, Dose-Escalation, Study to Assess the Safety and Pharmacodynamics of Single and Multiple Doses of QBKPN (Inactivated Klebsiella Pneumoniae) Site Specific Immunomodulator (SSI), Administered Subcutaneously to Healthy Male and Female Volunteers Withdrawn NCT02897999 Phase 1
15 Analysis on the Infection Risk, Prognosis, and Drug Sensitivity of Klebsiella Pneumoniae. Unknown status NCT04337840
16 Klebsiella Pneumoniae Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome Unknown status NCT03598543
17 WGS-guided Tracking and Infection Control Measures of Carbapenem-resistant Klebsiella Pneumoniae Unknown status NCT04413305
18 Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China Unknown status NCT03245632
19 Comparison of Clinical Outcomes in Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae (COMBAT) Unknown status NCT04229498 Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
20 Genetic Characterization of Plasmids Carrying Carbapenemases and Quinolone Resistance Determinants in Klebsiella Pneumoniae Isolates in Assiut University Hospitals Unknown status NCT03767283
21 How to Optimize the Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae Unknown status NCT03950544 Early Phase 1 Fosfomycin;Tigecycline;Polymyxin B
22 Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin Completed NCT02604849 Neomycin;Streptomycin;Gentamicins
23 Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species Completed NCT00518661
24 Double Carbapenem as Rescue Strategy for the Treatment of Severe Carbapenemase-Producing Klebsiella Pneumoniae Infections: A Two-Center Matched Case-Control Study Completed NCT03094494
25 Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units. Completed NCT00167999 piperacillin-tazobactam
26 Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae. Completed NCT00167986 vancomycin-resistant enterococci and ESBL
27 Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia: a National Multicenter Observational Study Completed NCT03597841 Combination therapy
28 Community - Associated Extended-spectrum Beta-lactamases (ESBL) Completed NCT00363220
29 A Randomized Open Label Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC). Completed NCT01266499 Colistin (Polymyxin E) 100mg x 4/d;both medications;will not receive PO treatment;PO Garamycin 80mg x 4/d
30 Sites of Colonization in Hospitalized Patients With Infections Caused by Extended-Spectrum Beta-Lactamase Producing Escherichia Coli and Klebsiella Pneumoniae Completed NCT01324726
31 Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features Completed NCT01139112
32 A Randomized,Double-Blind,Placebo-Controled Trial of Selective Digestive Decontamination Using Oral Gentamicin and Oral Polymyxin E for Eradication of Carbapenem-Resistant Klebsiella Pneumoniae Carriage Completed NCT00753558 Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
33 Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase (ESBL)Producing Escherichia Coli or Klebsiella Pneumoniae in China: Prevalence, Risk Factors and Prognosis Completed NCT01961206
34 Antimicrobial Resistance Rate In Escherichia Coli And Klebsiella Pneumonia : A Retrospective Study Completed NCT04196387
35 A Matched Case-control Study of Carbapenem Resistant and Carbapenem Sensitive Klebsiella Pneumoniae Infected Pyogenic Liver Abscess Completed NCT05521139
36 The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy Completed NCT01612182
37 Reducing Intraoperative ESKAPE (Enterococcus, S. Aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter Spp.) Transmission In the Pediatric Operating Room Via Use of a Personal Hand Hygiene System Optimized by OR PathTrac Completed NCT03992209
38 Analysis of the Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection: A Multi-center Research in the Intensive Care Units Completed NCT04404582
39 Epidemiological, Clinical, Microbiological and Outcome Description of Patients With Klebsiella sp Meningitis Completed NCT03967210
40 Switch to Oral Antibiotics in Gram-negative Bacteremia (SOAB); a Randomized, Open-label, Clinical Trial. Recruiting NCT04146922
41 Type VI Secretion System in Klebsiella Pneumoniae Relation to Antibiotic Resistance and Biofilm Formation Recruiting NCT05516654
42 Reducing Intraoperative ESKAPE (Enterococcus, S. Aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter Spp.) Transmission in the Adult Operating Room Via Use of a Personal Hand Hygiene System Optimized by OR PathTrac Recruiting NCT04900298
43 Prognosis and Virulence Determination of Capsule and Endotoxin During Klebsiella Spp. Ventilator-associated Pneumonias Recruiting NCT05450796
44 Incidence and Risk Factors for Developing Infections in Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae Recruiting NCT05492539
45 Prognosis of Klebsiella ESBL Sepsis: Role of 2-HYDRoxy-myristate in Endotoxin Structure Active, not recruiting NCT05193045
46 Fecal Microbiota Transplantation (FMT): PRIM-DJ2727 Available NCT03786900

Search NIH Clinical Center for Klebsiella Infection

Inferred drug relations via UMLS 71 / NDF-RT 50 :


cefditoren
CEFTIBUTEN DIHYDRATE
Ciprofloxacin
Enoxacin
lomefloxacin

Genetic Tests for Klebsiella Infection

Anatomical Context for Klebsiella Infection

Organs/tissues related to Klebsiella Infection:

MalaCards : Liver, Lung, Kidney, Whole Blood, Spinal Cord, Bone Marrow, Skin

Publications for Klebsiella Infection

Articles related to Klebsiella Infection:

(show top 50) (show all 30012)
# Title Authors PMID Year
1
Organic acid, phosphate, sulfate and ammonium co-metabolism releasing insoluble phosphate by Klebsiella aerogenes to simultaneously stabilize lead and cadmium. 62
36444069 2023
2
A set of antibiotic-resistance mechanisms and virulence factors in GES-16-producing Klebsiella quasipneumoniae subsp. similipneumoniae from hospital wastewater revealed by whole-genome sequencing. 62
36375580 2023
3
Klebsiella oxytoca (EN-B2): A novel type of simultaneous nitrification and denitrification strain for excellent total nitrogen removal during multiple nitrogen pollution wastewater treatment. 62
36332872 2023
4
The Method of Screening and Identification of Transcription Factor in Klebsiella. 62
36264485 2023
5
Odor-mediated response of gravid Aedes aegypti to mosquito-associated symbiotic bacteria. 62
36280207 2023
6
A wide clinical spectrum of pulmonary affection in subjects with community-acquired Klebsiella pneumoniae liver abscess (CA-KPLA). 62
36130707 2023
7
FeoC from Klebsiella pneumoniae uses its iron sulfur cluster to regulate the GTPase activity of the ferrous iron channel. 62
36182071 2023
8
Biogenic synthesis of ZnO nanoparticles mediated from Borassus flabellifer (Linn): antioxidant, antimicrobial activity against clinical pathogens, and photocatalytic degradation activity with molecular modeling. 62
35040048 2022
9
MCR-1-dependent lipid remodelling compromises the viability of Gram-negative bacteria. 62
35437117 2022
10
Melatonin ameliorates lung cell inflammation and apoptosis caused by Klebsiella pneumoniae via AMP-activated protein kinase. 62
36131109 2022
11
Virulence factors of uropathogens and their role in host pathogen interactions. 62
35198842 2022
12
Klebsiella pneumoniae liver abscess mimicking cholangiocarcinoma: A case report. 62
35718618 2022
13
Microbiological findings and prescribing trends in SARS- CoV-2 positive patients in two United Kingdom Hospitals. 62
36091659 2022
14
Microbial community succession in the fermentation of Qingzhuan tea at various temperatures and their correlations with the quality formation. 62
36155261 2022
15
Neutrophilic Pleuritis Is a Severe Complication of Klebsiella pneumoniae Pneumonia in Old Mice. 62
36426980 2022
16
Exploiting the Acidic Extracellular pH: Evaluation of Streptococcus salivarius M18 Postbiotics to Target Cancer Cells. 62
34080175 2022
17
Klebsiella Species and Enterobacter cloacae Isolates Harboring blaOXA-181 and blaOXA-48: Resistome, Fitness Cost, and Plasmid Stability. 62
36453894 2022
18
Detection of ESBL and AmpC producing Klebsiella pneumoniae ST11 and ST147 from urinary tract infections in Iran. 62
36112491 2022
19
Klebsiella pneumoniae ST147: and then there were three carbapenemases. 62
36271303 2022
20
Clonal Spread of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 11 in Chinese Pediatric Patients. 62
36453896 2022
21
Molecular epidemiology of carbapenem-resistant hypervirulent Klebsiella pneumoniae in China. 62
35236251 2022
22
Emergence of colistin-resistant hypervirulent Klebsiella pneumoniae (CoR-HvKp) in China. 62
35086435 2022
23
Interspecies differences in clinical characteristics and risk factors for third-generation cephalosporin resistance between Escherichia coli and Klebsiella pneumoniae bloodstream infection in patients with liver cirrhosis. 62
36227508 2022
24
Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature. 62
36183238 2022
25
Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest. 62
35811020 2022
26
Multiple detection of hypermucoviscous and hypervirulent strains of Klebsiella pneumoniae: An emergent health care threat. 62
36427200 2022
27
In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates. 62
36167781 2022
28
Causality of Opportunistic Pathogen Klebsiella pneumoniae to Hypertension Development. 62
36259407 2022
29
A large-scale genomic snapshot of Klebsiella spp. isolates in Northern Italy reveals limited transmission between clinical and non-clinical settings. 62
36411354 2022
30
Carbapenem-resistant Klebsiella pneumoniae outbreak in a COVID-19 intensive care unit; a case-control study. 62
35470780 2022
31
Simultaneous reductions in antibiotic, antibiotic resistance genes and nitrogen loss during bioaugmentation tylosin fermentation dregs co-composting. 62
35981593 2022
32
Etiology, antimicrobial resistance, and risk factors of neonatal sepsis in China: a systematic review and meta-analysis from data of 30 years. 62
34470123 2022
33
Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis. 62
35034585 2022
34
Metformin attenuated sepsis-related liver injury by modulating gut microbiota. 62
35191819 2022
35
Antibiotics-induced depression in mice via the microbiota-gut-brain axis. 62
36075400 2022
36
Comparison of obstetric to institutional antibiogram as an approach to advance antimicrobial stewardship in maternal care. 62
36117423 2022
37
Strong pathogen competition in neonatal gut colonisation. 62
36456554 2022
38
Epidemiology and Early Bacteriology of Extremely Severe Burns from an LPG Tanker Explosion in Eastern China. 62
36166166 2022
39
GOx-encapsulated iron-phenolic networks power catalytic cascade to eradicate bacterial biofilms. 62
36241091 2022
40
Plasmid sequence dataset of multidrug-resistant Enterobacterales isolated from hospital effluents and wastewater treatment plant. 62
36426060 2022
41
Occurrence and significance of fluoroquinolone-resistant and ESBL-producing Escherichia coli and Klebsiella pneumoniae complex of the rectal flora in Ghanaian patients undergoing prostate biopsy. 62
36349243 2022
42
Siderophore iucA of hypermucoviscous Klebsiella pneumoniae promotes liver damage in mice by inducing oxidative stress. 62
36340868 2022
43
Microscopic visualization of the antibiofilm potential of essential oils against Staphylococcus aureus and Klebsiella pneumoniae. 62
36250506 2022
44
Genomic characterization of BKC-1-producing Klebsiella pneumoniae strain belonging to high-risk clone sequence type 11 isolated from a river in Brazil. 62
35952879 2022
45
Outer membrane vesicles-transmitted virulence genes mediate the emergence of new antimicrobial-resistant hypervirulent Klebsiella pneumoniae. 62
35437096 2022
46
Exposure of multidrug-resistant Klebsiella pneumoniae biofilms to 1,8-cineole leads to bacterial cell death and biomass disruption. 62
36249125 2022
47
In vivo single-cell transcriptomics reveal Klebsiella pneumoniae skews lung macrophages to promote infection. 62
36337046 2022
48
Coexistence of Multidrug Resistance and Virulence in a Single Conjugative Plasmid from a Hypervirulent Klebsiella pneumoniae Isolate of Sequence Type 25. 62
36472445 2022
49
A geographic cluster of healthcare-associated carbapenemase-producing hypervirulent Klebsiella pneumoniae sequence type 23. 62
36454389 2022
50
A novel and improved selective media for the isolation and enumeration of Klebsiella species. 62
36380193 2022

Variations for Klebsiella Infection

Expression for Klebsiella Infection

Search GEO for disease gene expression data for Klebsiella Infection.

Pathways for Klebsiella Infection

GO Terms for Klebsiella Infection

Sources for Klebsiella Infection

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....